Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim

Favourable cost-efficacy analysis

Angelo Gardellini, F. Gigli, A. Babic, G. Andreola, D. Radice, S. Sammassimo, G. Martinelli, D. Laszlo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilisation and recovery after autologous stem cell transplantation. Method: With the aim of comparing cost-effective strategies in the use of G-CSF after autologous stem cell transplantation, we retrospectively evaluated 32 patients consecutively treated with biosimilar filgrastim XM02 (Tevagrastim) and 26 with lenograstim. All patients received G-CSF (biosimilar or lenograstim) at a dosage of 5 mcg/kg/day subcutaneously from day 5 to absolute neutrophil count of 1500/mmc for three days. Results: The median time to absolute neutrophil count engraftment was 11 days for the filgrastim XM02 group and 12 days for the lenograstim group. As for platelets recovery, the median time was 12 days in both groups. The median number of G-CSF vials used for patients was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 euros for Tevagrastim versus 932.2 euros for lenograstim (p <0.001). The median days of febrile neutropenia were 1.5 and 1 for filgrastim XM02 and lenograstim, respectively. No adverse event related to the use of XM02 filgrastim was recorded. Conclusion: In our experience, filgrastim XM02 and lenograstim showed comparable efficacy in shortening the period of neutropenia after cytoreduction and autologous stem cell transplantation, with a favourable cost effect for filgrastim XM02.

Original languageEnglish
Article number327
Journalecancermedicalscience
Volume7
Issue number1
DOIs
Publication statusPublished - Jun 20 2013

Fingerprint

Stem Cell Transplantation
Biosimilar Pharmaceuticals
Granulocyte Colony-Stimulating Factor
Costs and Cost Analysis
Neutrophils
Hematopoietic Stem Cell Mobilization
Febrile Neutropenia
lenograstim
Filgrastim
Neutropenia
Blood Platelets

Keywords

  • Autologous bone marrow transplantation
  • Biosimilar g-csf
  • Engraftment
  • Filgrastim
  • Lenograstim

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim : Favourable cost-efficacy analysis. / Gardellini, Angelo; Gigli, F.; Babic, A.; Andreola, G.; Radice, D.; Sammassimo, S.; Martinelli, G.; Laszlo, D.

In: ecancermedicalscience, Vol. 7, No. 1, 327, 20.06.2013.

Research output: Contribution to journalArticle

@article{a50baf8d78f84fd0806e86c1d45523e9,
title = "Filgrastim XM02 (Tevagrastim{\circledR}) after autologous stem cell transplantation compared to lenograstim: Favourable cost-efficacy analysis",
abstract = "Purpose: Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilisation and recovery after autologous stem cell transplantation. Method: With the aim of comparing cost-effective strategies in the use of G-CSF after autologous stem cell transplantation, we retrospectively evaluated 32 patients consecutively treated with biosimilar filgrastim XM02 (Tevagrastim) and 26 with lenograstim. All patients received G-CSF (biosimilar or lenograstim) at a dosage of 5 mcg/kg/day subcutaneously from day 5 to absolute neutrophil count of 1500/mmc for three days. Results: The median time to absolute neutrophil count engraftment was 11 days for the filgrastim XM02 group and 12 days for the lenograstim group. As for platelets recovery, the median time was 12 days in both groups. The median number of G-CSF vials used for patients was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 euros for Tevagrastim versus 932.2 euros for lenograstim (p <0.001). The median days of febrile neutropenia were 1.5 and 1 for filgrastim XM02 and lenograstim, respectively. No adverse event related to the use of XM02 filgrastim was recorded. Conclusion: In our experience, filgrastim XM02 and lenograstim showed comparable efficacy in shortening the period of neutropenia after cytoreduction and autologous stem cell transplantation, with a favourable cost effect for filgrastim XM02.",
keywords = "Autologous bone marrow transplantation, Biosimilar g-csf, Engraftment, Filgrastim, Lenograstim",
author = "Angelo Gardellini and F. Gigli and A. Babic and G. Andreola and D. Radice and S. Sammassimo and G. Martinelli and D. Laszlo",
year = "2013",
month = "6",
day = "20",
doi = "10.3332/ecancer.2013.327",
language = "English",
volume = "7",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",
number = "1",

}

TY - JOUR

T1 - Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim

T2 - Favourable cost-efficacy analysis

AU - Gardellini, Angelo

AU - Gigli, F.

AU - Babic, A.

AU - Andreola, G.

AU - Radice, D.

AU - Sammassimo, S.

AU - Martinelli, G.

AU - Laszlo, D.

PY - 2013/6/20

Y1 - 2013/6/20

N2 - Purpose: Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilisation and recovery after autologous stem cell transplantation. Method: With the aim of comparing cost-effective strategies in the use of G-CSF after autologous stem cell transplantation, we retrospectively evaluated 32 patients consecutively treated with biosimilar filgrastim XM02 (Tevagrastim) and 26 with lenograstim. All patients received G-CSF (biosimilar or lenograstim) at a dosage of 5 mcg/kg/day subcutaneously from day 5 to absolute neutrophil count of 1500/mmc for three days. Results: The median time to absolute neutrophil count engraftment was 11 days for the filgrastim XM02 group and 12 days for the lenograstim group. As for platelets recovery, the median time was 12 days in both groups. The median number of G-CSF vials used for patients was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 euros for Tevagrastim versus 932.2 euros for lenograstim (p <0.001). The median days of febrile neutropenia were 1.5 and 1 for filgrastim XM02 and lenograstim, respectively. No adverse event related to the use of XM02 filgrastim was recorded. Conclusion: In our experience, filgrastim XM02 and lenograstim showed comparable efficacy in shortening the period of neutropenia after cytoreduction and autologous stem cell transplantation, with a favourable cost effect for filgrastim XM02.

AB - Purpose: Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilisation and recovery after autologous stem cell transplantation. Method: With the aim of comparing cost-effective strategies in the use of G-CSF after autologous stem cell transplantation, we retrospectively evaluated 32 patients consecutively treated with biosimilar filgrastim XM02 (Tevagrastim) and 26 with lenograstim. All patients received G-CSF (biosimilar or lenograstim) at a dosage of 5 mcg/kg/day subcutaneously from day 5 to absolute neutrophil count of 1500/mmc for three days. Results: The median time to absolute neutrophil count engraftment was 11 days for the filgrastim XM02 group and 12 days for the lenograstim group. As for platelets recovery, the median time was 12 days in both groups. The median number of G-CSF vials used for patients was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 euros for Tevagrastim versus 932.2 euros for lenograstim (p <0.001). The median days of febrile neutropenia were 1.5 and 1 for filgrastim XM02 and lenograstim, respectively. No adverse event related to the use of XM02 filgrastim was recorded. Conclusion: In our experience, filgrastim XM02 and lenograstim showed comparable efficacy in shortening the period of neutropenia after cytoreduction and autologous stem cell transplantation, with a favourable cost effect for filgrastim XM02.

KW - Autologous bone marrow transplantation

KW - Biosimilar g-csf

KW - Engraftment

KW - Filgrastim

KW - Lenograstim

UR - http://www.scopus.com/inward/record.url?scp=84879624373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879624373&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2013.327

DO - 10.3332/ecancer.2013.327

M3 - Article

VL - 7

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

IS - 1

M1 - 327

ER -